IMPACT OF ERYTHROCYTES ANTIGENS ON DEVELOPMENT OF LIVER CIRRHOSIS
Introduction. High rates of prevalence and mortality of liver cirrhosis, it’s late clinical manifestation, disadvantages of liver biopsy highlight the background points of our research.
Aim. Research of erythrocytes’ antigens profile in patients with liver cirrhosis of Kazakh and Russian ethnical groups.
Materials and Methods: One hundred and forty patients with liver cirrhosis and 272 relatively healthy participants of both of nationalities were involved into research. АВ0, MNS, P1, CDE systems of erythrocytes of venous blood were investigated. For the comparison of the frequencies of phenotypes χ2 criterium, odds ratio (OR) and 95% confidence interval (CI) were used.
Results: Erythrocytes phenotypes 0 (I) (OR = 1.917, 95% CI 1,166-3,152), MN (OR = 2.868, 95% CI 1,749-4,704), P1 (+) (OR = 2.412, 95% CI 1,112-5,234), CC (OR = 2.149, 95% CI 1,310-3,526), D (+) (OR = 2.738, 95% CI 1,093-6,860), ee (OR = 1.854, 95% CI 1,092-3,148) in Kazakh patients and A (II) (OR = 2.653, 95% CI 1,063-6,622), MM (OR = 2.879, 95% CI 1,200-6,907), P1 (+) (OR = 3.352, 95% CI 1,383-8,126), Cc (OR = 6.968, 95% CI 2,581-18,812) in Russian patients are associated with liver cirrhosis development.
Conclusion: Our research showed that 0(I), MN, D+, CC, ee phenotypes are associated with development of liver cirrhosis in Kazakhs , as А(II), ММ, Сс, P1 isoantigens are related to development of disease in Russians
Laura Kassym, http://orcid.org/0000-0003-4448-6455
Zauresh K. Zhumadilova, Nurgul R. Barkibayeva
Semey State Medical University, Department of Internal diseases,
Semey, Republic of Kazakhstan
1. Гржибовский А.М., Иванов С.В. Исследования типа «случай-контроль» в здравоохранении // Наука и Здравоохранение. 2015. № 4. С. 5-17.
2. Надиров Ж.К., Бекиров Д.С., Каражигитова З.Б., Аманкулова Ш.К., Митерев Г.Ю., Оловникова Н.И. Методические рекомендации по использованию моноклональных антител в иммуногематологических исследованиях доноров и реципиентов. Алматы, 2010. с.8
3. Andrade R.J., Lucena M.I., Alonso A., García-Cortes M., García-Ruiz E., Benitez R. et al. HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease // Hepatology. 2004;39(6):1603-12.
4. Bedossa P.T. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C // Hepatology. 1994;20(1):15-20.
5. Ben Q., Wang K., Yuan Y., Li Z. Pancreatic cancer incidence and outcome in relation to ABO blood groups among Han Chinese patients: a case-control study // Int J Cancer. 2011;128(5):1179-86.
6. Ben-Ari Z., Czaja A.J. Autoimmune hepatitis and its variant syndromes // Gut. 2001;49(4):589-94.
7. Hautekeete M.L., Horsmans Y., Van Waeyenberge C., Demanet C., Henrion J., Verbist L., et al. HLA association of amoxicillin-clavulanate--induced hepatitis // Gastroenterology. 1999;117(5):1181-6.
8. Hein H.O., Suadicani P., Gyntelberg F. Genetic markers for stomach ulcer. A study of 3,387 men aged 54-74 years from The Copenhagen Male Study // Ugeskr Laeger. 1998;160(35):5045-9.
9. Kazakhstan: WHO statistical profile [Available from: http.://www.who.int/gho/kaz.pdf?ua=1
10. Kratzer W., de Lazzer K., Wiesneth M., Muche R., Kächele V. The effect of ABO, Rhesus and Kell blood group antigens on gallstone prevalence. A sonographic study of 1030 blood donors // Dtsch Med Wochenschr. 1999;124(19):579-83.
11. Lee H.F., Lin Y.C., Lin C.P., Wang C.L., Chang C.J., Hsu L.A. Association of blood group A with coronary artery disease in young adults in Taiwan // Intern Med. 2012;51(14):1815-20.
12. Lucarelli P., Scacchi R., Corbo R.M., Palmarino R., Orsini M., Campea L. et al. Genetic polymorphisms in juvenile-onset diabetes // Hum Hered. 1978;28(2):89-95.
13. Mackay I.R., Morris P.J. Association of autoimmune active chronic hepatitis with HL-A1,8 // Lancet. 1972;2(7781):793-5.
14. Marks I.N., Bank S., Barbezat G.O. Alkoholpankreatitis -- Atiologie, klinische Formen, Komplikationen // Leber Magen Darm. 1976 Oct;6(5):257–270.
15. Melato M., Sasso F., Zanconati F. Liver cirrhosis and liver cancer. A study of their relationship in 2563 autopsies // Zentralbl Pathol. 1993;139(1):25-30.
16. Nozawa Y., Umemura T., Joshita S., Katsuyama Y., Shibata S., Kimura T. et al. KIR, HLA, and IL28B variant predict response to antiviral therapy in genotype 1 chronic hepatitis C patients in Japan // PLoS One. 2013;8(12):e83381.
17. O'Donohue J., Oien K.A., Donaldson P., Underhill J., Clare M., MacSween R.N. et al. Co-amoxiclav jaundice: clinical and histological features and HLA class II association // Gut. 2000;47(5):717-20.
18. Rahbari N.N., Bork U., Hinz U., Leo A., Kirchberg J., Koch M., et al. AB0 blood group and prognosis in patients with pancreatic cancer // BMC Cancer. 2012;12:319.
19. Rockey D.C., Caldwell S.H., Goodman Z.D., Nelson R.C., Smith A.D. Diseases AAftSoL. Liver biopsy // Hepatology. 2009;49(3):1017-44.
20. Schuppan D, Afdhal NH. Liver Cirrhosis. // Lancet. 2008;371(9615):838-851. doi:10.1016/S0140-6736(08)60383-9.
21. Stättermayer A.F., Scherzer T., Beinhardt S., Rutter K., Hofer H., Ferenci P. Review article: genetic factors that modify the outcome of viral hepatitis // Aliment Pharmacol Ther. 2014;39(10):1059-70.
22. Stigendal L., Olsson R., Rydberg L., Samuelsson B.E. Blood group lewis phenotype on erythrocytes and in saliva in alcoholic pancreatitis and chronic liver disease // Journal of Clinical Pathology. 1984;37(7):778-782.
23. Szwed Z., Dybała T., Haczek-Kluczewska A., Pudełko M. AB0 and Rh blood groups as a risk factor of gallstone disease // Wiad Lek. 2007;60(11-12):531-4.
24. Tertti R., Järvinen H., Lahesmaa R., Yli-Kerttula U., Toivanen A. AB0 and Lewis blood groups in reactive arthritis // Rheumatol Int. 1992;12(3):103-5.
25. Vestbo J., Hein H.O., Suadicani P., Sørensen H., Gyntelberg F. Genetic markers for chronic bronchitis and peak expiratory flow in the Copenhagen Male Study // Dan Med Bull. 1993;40(3):378-80.
26. Wolpin B.M., Kraft P., Xu M., Steplowski E., Olsson M.L., Arslan A.A. et al. Variant ABO blood group alleles, secretor status, and risk of pancreatic cancer: results from the pancreatic cancer cohort consortium // Cancer Epidemiol Biomarkers Prev. 2010;19(12):3140-9.
27. Yan Z.H., Fan Y., Wang X.H., Mao Q., Deng G.H., Wang Y.M. Relationship between HLA-DR gene polymorphisms and outcomes of hepatitis B viral infections: a meta-analysis // World J Gastroenterol. 2012;18(24):3119-28.
References:
1. Grzhibovskii A. M., Ivanov S. V., Gorbatova M. A. Issledovaniya tipa «sluchai-kontrol» v zdravookhranenii ["Case-control" researches in health care]. Nauka i Zdravookhranenie [Science & Healthcare]. 2015, 4, pp. 5-17. [in Kazak]
2. Nadirov Zh.K., Bekirov D.S., Karazhigitova Z.B., Amankulova Sh.K., Miterev G.Ju., Olovnikova N.I. Metodicheskie rekomendacii po ispol'zovaniju monoklonal'nyh antitel v immunogematologicheskih issledovanijah donorov i recipientov [Guidelines on the use of monoclonal antibodies in the immunohematological studies of donors and recipients]. Almaty, 2010, p.8 [in Kazakh]
3. Andrade R.J., Lucena M.I., Alonso A., García-Cortes M., García-Ruiz E., Benitez R. et al. HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology. 2004;39(6):1603-12.
4. Bedossa P.T. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology. 1994;20(1):15-20.
5. Ben Q., Wang K., Yuan Y., Li Z. Pancreatic cancer incidence and outcome in relation to ABO blood groups among Han Chinese patients: a case-control study. Int J Cancer. 2011;128(5):1179-86.
6. Ben-Ari Z., Czaja A.J. Autoimmune hepatitis and its variant syndromes. Gut. 2001;49(4):589-94.
7. Hautekeete M.L., Horsmans Y., Van Waeyenberge C., Demanet C., Henrion J., Verbist L. et al. HLA association of amoxicillin-clavulanate--induced hepatitis. Gastroenterology. 1999;117(5):1181-6.
8. Hein H.O., Suadicani P., Gyntelberg F. Genetic markers for stomach ulcer. A study of 3,387 men aged 54-74 years from The Copenhagen Male Study. Ugeskr Laeger. 1998;160(35):5045-9.
9. Kazakhstan: WHO statistical profile [Available from: http.://www.who.int/gho/kaz.pdf?ua=1
10. Kratzer W., de Lazzer K., Wiesneth M., Muche R., Kächele V. The effect of ABO, Rhesus and Kell blood group antigens on gallstone prevalence. A sonographic study of 1030 blood donors. Dtsch Med Wochenschr. 1999;124(19):579-83.
11. Lee H.F., Lin Y.C., Lin C.P., Wang C.L., Chang C.J., Hsu L.A. Association of blood group A with coronary artery disease in young adults in Taiwan. Intern Med. 2012;51(14):1815-20.
12. Lucarelli P., Scacchi R., Corbo R.M., Palmarino R., Orsini M., Campea L. et al. Genetic polymorphisms in juvenile-onset diabetes. Hum Hered. 1978;28(2):89-95.
13. Mackay I.R., Morris P.J. Association of autoimmune active chronic hepatitis with HL-A1,8. Lancet. 1972;2(7781):793-5.
14. Marks I.N., Bank S., Barbezat G.O. Alkoholpankreatitis -- Atiologie, klinische Formen, Komplikationen. Leber Magen Darm. 1976 Oct;6(5):257–270.
15. Melato M., Sasso F., Zanconati F. Liver cirrhosis and liver cancer. A study of their relationship in 2563 autopsies. Zentralbl Pathol. 1993;139(1):25-30.
16. Nozawa Y., Umemura T., Joshita S., Katsuyama Y., Shibata S., Kimura T. et al. KIR, HLA, and IL28B variant predict response to antiviral therapy in genotype 1 chronic hepatitis C patients in Japan. PLoS One. 2013;8(12):e83381.
17. O'Donohue J., Oien K.A., Donaldson P., Underhill J., Clare M., MacSween R.N. et al. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut. 2000;47(5):717-20.
18. Rahbari N.N., Bork U., Hinz U., Leo A., Kirchberg J., Koch M. et al. AB0 blood group and prognosis in patients with pancreatic cancer. BMC Cancer. 2012;12:319.
19. Rockey D.C., Caldwell S.H., Goodman Z.D., Nelson R.C., Smith A.D. Diseases AAftSoL. Liver biopsy. Hepatology. 2009;49(3):1017-44.
20. Schuppan D., Afdhal N.H. Liver Cirrhosis. Lancet. 2008; 371(9615): 838-851. doi:10.1016/S0140-6736(08)60383-9.
21. Stättermayer A.F., Scherzer T., Beinhardt S., Rutter K., Hofer H., Ferenci P. Review article: genetic factors that modify the outcome of viral hepatitis. Aliment Pharmacol Ther. 2014; 39(10): 1059-70.
22. Stigendal L., Olsson R., Rydberg L., Samuelsson B.E. Blood group lewis phenotype on erythrocytes and in saliva in alcoholic pancreatitis and chronic liver disease. Journal of Clinical Pathology. 1984; 37(7): 778-782.
23. Szwed Z., Dybała T., Haczek-Kluczewska A., Pudełko M. [AB0 and Rh blood groups as a risk factor of gallstone disease]. Wiad Lek. 2007; 60(11-12): 531-4.
24. Tertti R., Järvinen H., Lahesmaa R., Yli-Kerttula U., Toivanen A. AB0 and Lewis blood groups in reactive arthritis. Rheumatol Int. 1992; 12(3): 103-5.
25. Vestbo J., Hein H.O., Suadicani P., Sørensen H., Gyntelberg F. Genetic markers for chronic bronchitis and peak expiratory flow in the Copenhagen Male Study. Dan Med Bull. 1993; 40(3): 378-80.
26. Wolpin B.M., Kraft P., Xu M., Steplowski E., Olsson M.L., Arslan A.A. et al. Variant ABO blood group alleles, secretor status, and risk of pancreatic cancer: results from the pancreatic cancer cohort consortium. Cancer Epidemiol Biomarkers Prev. 2010; 19(12): 3140-9.
27. Yan Z.H., Fan Y., Wang X.H., Mao Q., Deng G.H., Wang Y.M. Relationship between HLA-DR gene polymorphisms and outcomes of hepatitis B viral infections: a meta-analysis. World J Gastroenterol. 2012; 18(24): 3119-28.
Number of Views: 323
Category of articles:
Original articles
Bibliography link
Касым Л., Жумадилова З.К., Баркибаева Н.Р. Влияние эритроцитарных изоантигенов на развитие цирроза печени / / Наука и Здравоохранение. 2016. № 5. С. 80-89 Kassym L., Zhumadilova Z.K., Barkibayeva N.R. Impact of erythrocytes’ antigens on development of liver cirrhosis. Nauka i Zdravookhranenie [Science & Healthcare]. 2016, 5, pp. 80-89 Касым Л., Жумадилова З.К., Баркибаева Н.Р. Эритроцитарлық изоантигендердің бауыр циррозының дамуына әсері / / Ғылым және Денсаулық сақтау. 2016. № 5. Б. 80-89Related publications:
ANALYSIS OF CLINICAL AND DEMOGRAPHIC INDICATORS OF PATIENTS WITH PARKINSON'S DISEASE IN THE SOUTHERN REGION OF KAZAKHSTAN
A COMPARATIVE STUDY OF DRUG POLICY REGARDING ORPHAN DISEASES IN THE USA, THE EUROPEAN UNION, AND THE REPUBLIC OF KAZAKHSTAN
MUTATIONS IN CARDIAC ION CHANNEL GENES IN KAZAKHSTANI PATIENTS WITH LONG QT SYNDROME
GENETIC FEATURES OF CONGENITAL DYSFUNCTION OF THE ADRENAL CORTEX CAUSED BY 21-HYDROXYLASE DEFICIENCY IN PERSONS OF KAZAKH NATIONALITY
NON-MOTOR SYMPTOMS IN PARKINSON'S DISEASE USING THE EXAMPLE OF AKTOBE PATIENTS